- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML | 128 | GlobeNewswire (Europe) | Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 16.10. | Cero Therapeutics passt Kaufvertrag an und sichert sich 2,25 Mio. US-Dollar im ersten Closing | 3 | Investing.com Deutsch | ||
| 15.10. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 | 2 | GlobeNewswire (USA) | ||
| 14.10. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.10. | CERo Therapeutics completes first cohort in AML clinical trial | 2 | Investing.com | ||
| 13.10. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML | 113 | GlobeNewswire (Europe) | Study's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently published... ► Artikel lesen | |
| 10.10. | CERo Therapeutics open to takeover offers as it awaits key data - Axios | 9 | Investing.com | ||
| 10.10. | CERo Therapeutics signalisiert vor wichtigen Studiendaten Verkaufsbereitschaft | 2 | Investing.com Deutsch | ||
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.09. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.09. | CERo Therapeutics doses third patient in AML clinical trial | 1 | Investing.com | ||
| 22.09. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort | 189 | GlobeNewswire (Europe) | Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO... ► Artikel lesen | |
| 09.09. | CERo Therapeutics secures key patent protection for cancer therapy | 1 | Investing.com | ||
| 09.09. | CERo Therapeutics sichert wichtigen US-Patentschutz für Krebstherapie | 3 | Investing.com Deutsch | ||
| 09.09. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 | 1 | GlobeNewswire (USA) | ||
| 08.09. | CERo Therapeutics administers second dose in AML clinical trial | 1 | Investing.com | ||
| 08.09. | CERo Therapeutics verabreicht zweite Dosis in klinischer AML-Studie | 2 | Investing.com Deutsch | ||
| 08.09. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia | 84 | GlobeNewswire (Europe) | Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE... ► Artikel lesen | |
| 05.09. | CERo Therapeutics Stock Drops 13% Despite FDA Fast Track For Lead AML Therapy | 1 | RTTNews | ||
| 05.09. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML) | 185 | GlobeNewswire (Europe) | Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company's lead cancer immunotherapy program SOUTH SAN FRANSCISCO... ► Artikel lesen | |
| 04.09. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,708 | +2,02 % | PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| CARISMA THERAPEUTICS INC | 0,023 | -7,72 % | XFRA W2J: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,914 | +2,75 % | CytomX Therapeutics Inc.: CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer | SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 4,220 | +0,48 % | Minerva Neurosciences: NBC-Tipp wird zum Tenbagger! | Anfang des Monats berichteten wir über hohe Preissprünge bei der Aktie von Minerva Neurosciences. Jetzt ist klar: Das anfängliche Kursspektakel bei der Biotech-Empfehlung des No Brainer Club war lediglich... ► Artikel lesen | |
| CORMEDIX | 9,600 | -1,54 % | CorMedix, Inc.: CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance | - Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million - Q3 2025 Unaudited DefenCath Net Revenue of more than $85 million - Raising FY 2025 Pro Forma Net Revenue Guidance to at least $375... ► Artikel lesen | |
| REPLIMUNE | 7,550 | +4,14 % | Replimune, Inc.: Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma | WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,065 | 0,00 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| IO BIOTECH | 1,010 | 0,00 % | IO Biotech Reveals Positive Phase 3 Results For Cylembio Plus Keytruda In Advanced Melanoma | KENILWORTH (NJ) (dpa-AFX) - IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 11,160 | 0,00 % | Alto Neuroscience stock soars after FDA meeting clears path for depression drug | ||
| OSR HOLDINGS | 0,634 | 0,00 % | Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target | New York, New York--(Newsfile Corp. - October 20, 2025) - Emerging Growth Research today announced the initiation of coverage on OSR Holdings, Inc. (NASDAQ: OSRH) with a Buy-Emerging rating and a 12-month... ► Artikel lesen | |
| QIAGEN | 42,270 | +0,49 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 48,550 | +3,61 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| ARCELLX | 84,07 | +0,85 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 6,590 | 0,00 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,250 | +0,53 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
CERO THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,010 (-0,50 %) liegt der Kurs bei 2,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.